Leukaemia Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• A parent or legal guardian has signed and dated the consent form agreeing to their child's participation.
• The child is under 18 years old and has been diagnosed with a liver condition called PNAC (parenteral nutrition-associated cholestasis), meaning their liver is not working properly due to being fed through an IV line, with no other known cause for the liver problem — and they are expected to need the study treatment (Omegaven) for at least 8 weeks.
• The child cannot tolerate being fed by mouth or through a feeding tube, or has at least one digestive system problem that requires them to be fed through an IV line.

Who may not be able to join:

• The child has received the study drug (Omegaven) within the last four weeks.
• The child has another known cause of long-term liver disease, such as hepatitis C, cystic fibrosis, biliary atresia, alpha-1-antitrypsin deficiency, or liver problems caused by heart failure.
• The child has been diagnosed with cirrhosis (severe scarring of the liver).
• The child has been diagnosed with, or has shown signs of, a blood clot in the portal vein (a major vein that carries blood to the liver).
• The child has previously had a liver transplant (either liver alone or liver along with another organ).
• The child has an unstable heart condition that affects blood flow throughout the body.
• The child has a serious, life-threatening illness such as severe blood infection (sepsis) requiring high-level medications, severe lung failure, or cancer.
• The child has multiple organ failure, severe low blood pressure, serious lung pressure problems, or requires a machine to support their heart and lung function (such as ECMO).
• The child has kidney failure that requires a machine to do the work of the kidneys (dialysis or similar treatment).
• The child has a serious bleeding disorder.
• The child has very high levels of fats (specifically triglycerides) in their blood, above 1,000 mg/dL.
• The child has a history of essential fatty acid deficiency (a condition where the body lacks certain important fats) before joining the study.
• The child has been diagnosed with, or is suspected to have, an inherited condition affecting how their body processes food and nutrients (inborn error of metabolism).
• The child is allergic to fish, egg protein, or any ingredient in Omegaven.
• The child is subject to any limitations on their medical treatment (confirm with trial site).
• The child is currently taking part in another clinical trial involving an experimental medication.

Important: Always verify eligibility with the trial site directly before applying.